YUN takes the stage in Prague

“The take-home message of the Bausch Launch Event: same dermatology. New biological target: the skin microbiome.”

YUN takes the stage in Prague l Ingmar Claes
 On October 15, our Chief Scientific Officer Ingmar Claes presented at the Bausch Health Companies Inc. Launch Event in Prague, a scientific evening bringing together dermatologists and healthcare professionals. The programme consisted of three lectures and a panel discussion, covering microbiome dysbiosis, antibiotic resistance in current treatment and probiotherapy as a novel approach to restoring skin balance.

Probiotherapy: A novel approach to restoring skin balance

The third lecture of the evening focused on the scientific foundations of probiotherapy and its practical positioning in dermatological care. Starting from the origins of the concept, the presentation walked through the key differences between prebiotics, probiotics and postbiotics, and why ingredients commonly used in cosmetics are not equivalent to live probiotics. The mechanisms of action of topical lactobacilli, the rationale for strain-specific selection and the role of microencapsulation in maintaining bacterial viability were all addressed, alongside a comparison with other products claiming to contain live bacteria. The presentation also covered how pre, pro and postbiotic products can complement one another in acne-prone and atopic skin care, and explored the potential of probiotherapy across other indications, including intimate care.

A shared microbiome target

Acne and atopic dermatitis involve more than inflammation alone. Dysbiosis creates a shared microbiome target within familiar dermatological pathways. Skin microbiome dysbiosis, including altered microbial activity, reduced diversity, barrier dysfunction and pathobiont expansion, is a common denominator of both conditions. Established treatments remain essential, while antibiotic resistance and non-target microbiome effects reinforce the need for complementary approaches.

The take-home message of the evening: same dermatology. New biological target: the skin microbiome.

Clinical perspectives from the panel

The programme also included a panel discussion in which two dermatologists shared their practical experience with probiotherapy in patients with acne and atopic dermatitis, offering insight into how the approach is being integrated into clinical practice.

Scientific basis

The presentations were supported by peer-reviewed research, including Lebeer et al. in Cell Reports Medicine (2022) on topical lactobacilli selectively targeting skin pathobionts and inflammation, Blaser in Nature (2011) on protecting beneficial bacteria and microbiome diversity, and Sultana et al. in Applied and Environmental Microbiology (2013) on lactobacilli and epithelial barrier integrity. Presented evidence also included placebo-controlled acne data and exploratory atopic dermatitis observations.

Ready to explore what Probiotherapy could add to your market?

➡️ Partner with YUN

Share this article:

Read more about your microbiome

From antibiotic protocols to ecosystem protocols: rethinking AMR in veterinary care
Animal

From antibiotic protocols to ecosystem protocols: rethinking AMR in veterinary care

“Protocols are evolving from antibiotic-centred decision trees to ecosystem-based care pathways. This shift isn’t just regulatory. It’s biological.”

Old friend hypothesis
Probiotherapy

Old friend hypothesis

“Many of today’s inflammatory and recurrent skin conditions are not caused by too many microbes, but by losing contact with the right ones. Understanding these old friends is reshaping how we think about skin health, treatment strategies and the future of microbiome‑based care.”

Rethinking fungal skincare: why microbiome restoration matters
FNG

Rethinking fungal skincare: why microbiome restoration matters

“Fungal skin conditions, from athlete’s foot to skin fold infections and recurring fungal irritations, affect millions across all age groups.”

Probiotherapy

Partnership with We The Bacteria: reimagining our relationship with microbes

“A thought-provoking exhibition at DE SINGEL in Antwerp that challenges the way we think about bacteria, health and the environments we live in.”

How consumers experience YUN Probiotherapy: insights from 78 real‑world testers
ACN

How consumers experience YUN Probiotherapy: insights from 78 real‑world testers

“Over four weeks, 78 testers used complete routines from the ATO (atopic dermatitis) or ACN (acne) lines and evaluated each product on effectiveness, feel, composition and overall satisfaction.”

Probiotherapy

From Belgian biotech to international growth

“From Belgian biotech to international growth: Bausch Health and YUN expand to Mexico and across EMEA.”

Animal

What if supporting the ear microbiome could change how we approach ear care in dogs?

“Antimicrobial resistance remains a growing global challenge, including in veterinary medicine.”

Probiotherapy

Antimicrobial resistance is accelerating. Dermatology needs a new model.

“The future of skin health is not more destruction. It is precision with preservation.”

VGN

Understanding the vaginal microbiome: why balance matters for skin health

“In a healthy vaginal microbiome, Lactobacilli dominate not by coincidence, but by function.”

Probiotherapy

We believe in the bacterial revolution

“Within eighteen months, our YUN products will reach two billion people worldwide,” says our founder & CEO Tom Verlinden.

Probiotherapy

Why measuring microbial impact matters: inside YUN’s Microbiome Safe Scoring System

“Mild is not the same as microbiome-safe. Our scoring system shows the difference. Microbiome safety is measurable and the bacteria tell us the truth.”

Stay in tune with your skin

Receive emails with studies, practical tips and news about our products.